PP01.48: ARTEMIDE-Lung03: A Phase 3, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-Based Chemotherapy as First-Line Treatment for Patients with Metastatic Non-Squamous Non-Small-Cell Lung Cancer Whose Tumors Express PD-L1

Journal of Thoracic Oncology 2026

View at publisher
Authors: Christine M. Bestvina, Clarissa Mathias, Yasushi Goto, Carolin Gross-Ophoff-Mueller, Shun Lu, Delvys Rodríguez‐Abreu, Alona Zer, Moritz Drachsler, Maozhen Gong, James Hurlock, Jakub Tyszecki, Byoung Chul Cho
DOI: 10.1016/j.jtho.2026.103791
Cited by: 1

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies

Publication details

Journal / source
Journal of Thoracic Oncology
Publisher
Elsevier BV
Volume
21
Issue
5
Pages
103791–103791
Publication date
1 May 2026
Language
EN